Castellanos EH - Search Results

1

Clinical Response to Anti-Programmed Death 1 After Response and Subsequent Progression on Anti-Programmed Death Ligand 1 Therapy.

Castellanos EH, Feld E, Estrada MV, Sanders ME, Massion PP, Johnson DB, Balko JM, Horn L. Castellanos EH, et al. JCO Precis Oncol. 2017 Aug 15;1:PO.17.00049. doi: 10.1200/PO.17.00049. eCollection 2017. JCO Precis Oncol. 2017. PMID: 32913978 Free PMC article. No abstract available.

2

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer.

Castellanos E, Feld E, Horn L. Castellanos E, et al. J Thorac Oncol. 2017 Apr;12(4):612-623. doi: 10.1016/j.jtho.2016.12.014. Epub 2016 Dec 23. J Thorac Oncol. 2017. PMID: 28017789 Free article. Review.

3

Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.

Johnson DB, Nixon MJ, Wang Y, Wang DY, Castellanos E, Estrada MV, Ericsson-Gonzalez PI, Cote CH, Salgado R, Sanchez V, Dean PT, Opalenik SR, Schreeder DM, Rimm DL, Kim JY, Bordeaux J, Loi S, Horn L, Sanders ME, Ferrell PB Jr, Xu Y, Sosman JA, Davis RS, Balko JM. Johnson DB, et al. JCI Insight. 2018 Dec 20;3(24):e120360. doi: 10.1172/jci.insight.120360. JCI Insight. 2018. PMID: 30568030 Free PMC article.

4

Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress.

Castellanos EH, Horn L. Castellanos EH, et al. Curr Treat Options Oncol. 2015 Oct;16(10):51. doi: 10.1007/s11864-015-0365-1. Curr Treat Options Oncol. 2015. PMID: 26364032 Review.

5

Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.

Castellanos EH, Horn L. Castellanos EH, et al. Oncologist. 2016 Jun;21(6):755-61. doi: 10.1634/theoncologist.2015-0396. Epub 2016 Apr 6. Oncologist. 2016. PMID: 27053502 Free PMC article. Review.

6

Immunotherapy in Lung Cancer.

Castellanos EH, Horn L. Castellanos EH, et al. Cancer Treat Res. 2016;170:203-23. doi: 10.1007/978-3-319-40389-2_10. Cancer Treat Res. 2016. PMID: 27535396 Free PMC article. Review.

7

Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor--Mutated Non--Small-Cell Lung Cancer With T790M Mutations.

Castellanos EH, Rivera G, Wakelee H, Horn L. Castellanos EH, et al. Clin Lung Cancer. 2015 Sep;16(5):e97-9. doi: 10.1016/j.cllc.2015.02.005. Epub 2015 Mar 5. Clin Lung Cancer. 2015. PMID: 25842367 No abstract available.

8

Making the Grade: The Impact of Low-Grade Toxicities on Patient Preference for Treatment With Novel Agents.

Castellanos EH, Chen SC, Drexler H, Horn L. Castellanos EH, et al. J Natl Compr Canc Netw. 2015 Dec;13(12):1490-5. doi: 10.6004/jnccn.2015.0177. J Natl Compr Canc Netw. 2015. PMID: 26656518

9

Current treatment options for pancreatic carcinoma.

Castellanos E, Berlin J, Cardin DB. Castellanos E, et al. Curr Oncol Rep. 2011 Jun;13(3):195-205. doi: 10.1007/s11912-011-0164-1. Curr Oncol Rep. 2011. PMID: 21491194 Review.

10

Impact of patient symptoms and caregiving tasks on psychological distress in caregivers for head and neck cancer (HNC).

Castellanos EH, Dietrich MS, Bond SM, Wells N, Schumacher K, Ganti AK, Murphy BA. Castellanos EH, et al. Psychooncology. 2019 Mar;28(3):511-517. doi: 10.1002/pon.4968. Epub 2019 Jan 20. Psychooncology. 2019. PMID: 30578599

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28 results

Search Page